Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.70 |
| ▸ | CNR1 | P21554 | 8/20 | 0.70 |
| ▸ | PLK1 | P53350 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9340471 | 1.00 | CNR2 (0.70) | CNR2CNR1PLK1ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL2035939 | 0.99 | CNR2 (0.68) | CNR2CNR1PLK1ALDH1A1KDM4E | |
| SCHEMBL12643110 | 0.99 | CNR2 (0.69) | CNR2CNR1PLK1ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL2041733 | 0.97 | CNR2 (0.67) | CNR2CNR1PLK1ALDH1A1KDM4E | |
| SCHEMBL9540544 | 0.92 | PLK1 (0.66) | CNR2CNR1PLK1ALDH1A1KDM4E | |
| SCHEMBL9344335 | 0.92 | PLK1 (0.66) | CNR2CNR1PLK1ALDH1A1KDM4E | |
| SCHEMBL6870502 | 0.90 | CNR1 (0.71) | CNR2CNR1 | |
| SCHEMBL12168494 | 0.88 | CNR1 (0.70) | CNR2CNR1 | |
| SCHEMBL2045110 | 0.84 | CNR2 (0.64) | CNR2CNR1PLK1ALDH1A1KDM4E | |
| SCHEMBL9340446 | 0.83 | IDO1 (0.51) | CNR2CNR1PLK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829028-B2 | 5-HT4 receptor antagonists for the treatment of heart failure | SERODUS AS (NO) | 2014-09-09 | — | — | US | claimed |
| EP-1503764-B1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | SERODUS AS (NO) | 2010-01-06 | — | — | EP | claimed |
| US-20090169545-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | SERODUS AS (NO) | 2009-07-02 | — | — | US | claimed |
| US-20060094715-A1 | 5-Ht4 receptor antagonists for the treatment of heart failure | SERODUS AS (NO) | 2006-05-04 | — | — | US | claimed |
| EP-1503764-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | MEDINNOVA AS (NO) | 2005-02-09 | — | — | EP | claimed |
| WO-2003097065-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | MEDINNOVA AS (NO) | 2003-11-27 | — | — | WO | claimed |
| EP-1307184-A2 | DRUGS FOR INCONTINENCE | NICOX S.A. (FR) | 2003-05-07 | — | — | EP | claimed |
| WO-2002011707-A2 | DRUGS FOR INCONTINENCE | NICOX S.A. (FR) | 2002-02-14 | — | — | WO | claimed |
| EP-2305213-B1 | The treatment of small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions | CEDARS SINAI MEDICAL CENTER (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2267445-B1 | Methods of detecting small intestinal bacterial overgrowth (SIBO) in a human subject | CEDARS SINAI MEDICAL CENTER (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20150306190-A1 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS-SINAI MEDICAL CENTER (US) | 2015-10-29 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| EP-1385476-A4 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS SINAI MEDICAL CENTER (US) | 2006-06-14 | — | — | EP | disclosed |
| US-7048906-B2 | Calibration; administering antiseptic compound | CEDARS-SINAI MEDICAL CENTER (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-14 | — | — | US | disclosed |
| EP-1385476-A2 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS-SINAI MEDICAL CENTER (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083926-A2 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS | CEDARS-SINAI MEDICAL CENTER (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085477-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia | TPH2, TPH1, HTR2A | CNR2 44/4885CNR1 117/4885PLK1 280/4885 |
| US-20050080084-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage | TPH2, TPH1, HTR2A | CNR2 35/4885CNR1 88/4885PLK1 317/4885 |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | CNR2 113/4885CNR1 160/4885PLK1 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.